Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra L Lasho, Christy M. Finke, Michelle Amundson, Kristen McCullough, Betsy LaPlant, Abhishek A Mangaonkar, Naseema Gangat, Kaaren K Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood blood.2024024962.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Zhuoer Xie, Kristen McCullough, Terra L Lasho, Jenna A. Fernandez, Christy M Finke, Michelle Renee Amundson, Betsy LaPlant, Abhishek Mangaokar, Naseema Gangat, Kaaren K. Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2023-186595

Published: 2023

Journal Articles

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Naseema Gangat, Omer Karrar, Maymona Abdelmagid, Moazah Iftikhar, Kaaren K. Reichard, Natasha Szuber, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2023-179596

Published: 2023

Journal Articles

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

Abhishek A Mangaonkar, Terra L Lasho, Justin Boysen, Christy M Finke, Jenna A. Fernandez, Jose. C. Villasboas, Christopher Dean, Alejandro Ferrer, Moritz Binder, Liguo Wang, Jeong-Heon Lee, Kaaren K. Reichard, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2023-186856

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Maymona Abdelmagid, Jeanne Palmer, James M. Foran, Aref Al-Kali, Omer Karrar, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2023-180235

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Zhuoer Xie, Kristen McCullough, Terra Lasho, Jenna A. Fernandez, Christy Finke, Michelle Renee Amundson, Betsy Laplant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle A Elliott, Thomas E. Witzig, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 2893–2894.

https://doi.org/10.1182/blood-2022-165163

Published: 2022

Journal Articles

DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways

Jenna A. Fernandez, Bhavisha A. Patel, Fernanda Gutierrez-Rodrigues, Yael Kusne, Terra Lasho, Christy Finke, Matthew Koster, Abhishek A. Mangaonkar, Naseema Gangat, Kenneth Warrington, Kaaren K. Reichard, Horatiu Olteanu, Peter C. Grayson, Neal S. Young, David B. Beck, Mrinal M. Patnaik

Blood (2022) 140 (Supplement 1): 11410–11411.

https://doi.org/10.1182/blood-2022-167359

Published: 2022

Journal Articles

Monocytopenia As an Adverse Prognosticator in Vexas Syndrome

Yael Kusne, Matthew Koster, Kenneth Warrington, Ronald Go, Terra Lasho, Christy Finke, Jenna A. Fernandez, Kebede Begna, Allison M. Bock, Kaaren K. Reichard, Horatiu Olteanu, Jennifer Herrick, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 11406–11407.

https://doi.org/10.1182/blood-2022-165706

Published: 2022

Journal Articles

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Maymona Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Abhishek A. Mangaonkar, Mrinal M.M. Patnaik, Michelle A Elliott, Hassan B. Alkhateeb, Min Shi, Matthew Howard, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9735–9736.

https://doi.org/10.1182/blood-2022-163450

Published: 2022

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

https://doi.org/10.1182/blood-2022-163518

Published: 2022

Journal Articles

Clonal Hematopoiesis in Vexas Syndrome

Blood (2022) 140 (Supplement 1): 5745–5746.

https://doi.org/10.1182/blood-2022-160263

Published: 2022

Journal Articles

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Animesh Pardanani, Ayalew Tefferi, Amritpal Singh, Aref Al-Kali, Mrinal M. Patnaik, William J. Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen

Blood (2022) 140 (Supplement 1): 6872–6873.

https://doi.org/10.1182/blood-2022-167720

Published: 2022

Journal Articles

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H. Begna, Mrinal M. Patnaik, Aref Al-Kali, Michelle A Elliott, Kaaren K. Reichard, Naseema Gangat, Animesh D. Pardanani

Blood (2021) 138 (Supplement 1): 3657.

https://doi.org/10.1182/blood-2021-151009

Published: 2021

Journal Articles

Histopathologic Characterization of Vexas Syndrome

Mohammad I. Barouqa, Aishwarya Ravindran, Dong Chen, Jennifer L Oliveira, Horatiu Olteanu, Matthew T Howard, Gang Zheng, Mrinal M. Patnaik, Kebede H. Begna, Allison M. Bock, Ronald Go, Matthew Koster, Taxiarchis Kourelis, Abhishek A. Mangaonkar, Jay Ryu, Matthew Samec, Julio C. Sartori Valinotti, Kenneth Warrington, Kaaren K. Reichard

Blood (2021) 138 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2021-152739

Published: 2021

Journal Articles

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-134963

Published: 2020

Journal Articles

Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139050

Published: 2020

Journal Articles

Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm

Aishwarya Ravindran, MBBS, Rong He, MD, Majd D. Jawad, MD, Rhett P. Ketterling, Dong Chen, MD PhD, Jennifer L. Oliveira, MD, Phuong L. Nguyen, MD, David S. Viswanatha, MD, Kaaren K. Reichard, MD, James D. Hoyer, MD, Ronald S. Go, MD, Min Shi, MD PhD

Blood (2018) 132 (Supplement 1): 4382.

https://doi.org/10.1182/blood-2018-99-117821

Published: 2018

NARROW

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways

Monocytopenia As an Adverse Prognosticator in Vexas Syndrome

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Clonal Hematopoiesis in Vexas Syndrome

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

Histopathologic Characterization of Vexas Syndrome

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only